Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.

MLA

Tong, Wei-Gang, et al. “Imatinib Front-Line Therapy Is Safe and Effective in Patients with Chronic Myelogenous Leukemia with Pre-Existing Liver and/or Renal Dysfunction.” Cancer, vol. 116, no. 13, July 2010, pp. 3152–59. EBSCOhost, https://doi.org/10.1002/cncr.25071.

APA

Tong, W.-G., Kantarjian, H., O’Brien, S., Faderl, S., Ravandi, F., Borthakur, G., Shan, J., Pierce, S., Rios, M. B., & Cortes, J. (2010). Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer, 116(13), 3152–3159. https://doi.org/10.1002/cncr.25071

Chicago

Tong, Wei-Gang, Hagop Kantarjian, Susan O’Brien, Stefan Faderl, Farhad Ravandi, Gautam Borthakur, Jianqin Shan, Sherry Pierce, Mary Beth Rios, and Jorge Cortes. 2010. “Imatinib Front-Line Therapy Is Safe and Effective in Patients with Chronic Myelogenous Leukemia with Pre-Existing Liver and/or Renal Dysfunction.” Cancer 116 (13): 3152–59. doi:10.1002/cncr.25071.